These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Novel agents in the treatment of Waldenström's macroglobulinemia. Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845 [TBL] [Abstract][Full Text] [Related]
25. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Leblond V; Kastritis E; Advani R; Ansell SM; Buske C; Castillo JJ; García-Sanz R; Gertz M; Kimby E; Kyriakou C; Merlini G; Minnema MC; Morel P; Morra E; Rummel M; Wechalekar A; Patterson CJ; Treon SP; Dimopoulos MA Blood; 2016 Sep; 128(10):1321-8. PubMed ID: 27432877 [TBL] [Abstract][Full Text] [Related]
26. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report. D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999 [TBL] [Abstract][Full Text] [Related]
27. Preclinical models of Waldenström's macroglobulinemia and drug resistance. Ailawadhi S; Paulus A; Chanan-Khan A Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463 [TBL] [Abstract][Full Text] [Related]
28. Current therapy guidelines for Waldenstrom's macroglobulinaemia. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466 [TBL] [Abstract][Full Text] [Related]
29. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia. García-Sanz R; Tedeschi A Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089 [TBL] [Abstract][Full Text] [Related]
30. Managing Waldenström's macroglobulinemia with BTK inhibitors. Buske C; Jurczak W; Salem JE; Dimopoulos MA Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930 [TBL] [Abstract][Full Text] [Related]
35. [New developments in Waldenström's macroglobulinemia]. Grunenberg A; Buske C Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979 [TBL] [Abstract][Full Text] [Related]
37. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Kapoor P; Paludo J; Ansell SM Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591 [TBL] [Abstract][Full Text] [Related]
38. Report of consensus panel 1 from the 11 Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027 [TBL] [Abstract][Full Text] [Related]